Navigation Links
Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity

SAN DIEGO, May 29, 2015 /PRNewswire/ -- Epic Sciences announced today that the company will present single cell sequencing data, from metastatic castrate resistant prostate cancer patients, at the 2015 annual meeting of the American Society for Clinical Oncology. This application expands the investigational utility of Epic Sciences' no cell left behind™ platform to characterize circulating tumor cell (CTC) genomic alterations. The study revealed that late stage patients have heterogeneous clonal CTC populations harboring separate genetic alterations. Furthermore, the data show an association between CTC copy number alterations and phenotypic features, in terms of both cellular morphology and resistance to therapy. The study, titled "Intra-patient genomic heterogeneity of single circulating tumor cells (CTCs) associated to phenotypic CTC heterogeneity in metastatic castrate resistant prostate cancer (mCRPC)," was conducted in collaboration with clinical investigators at Memorial Sloan Kettering Cancer Center.

"The data presented at ASCO underscore the importance of evaluating an individual patient's disease on a cell by cell basis to identify the frequency of specific clonal populations that influence prognosis and sensitivity to different forms of therapy," said Dr. Howard I. Scher, Chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan Kettering and senior author. "There is a great deal of tumor heterogeneity in late stage cancer and identifying the individual clones and the genetic alterations driving their continued growth may help guide treatment selection and accelerate or better enable drug development."

In the study, 337 CTCs from 17 patients were individually isolated and characterized for cell morphology, molecular and genomic markers. Genetic material from each individual cell was sequenced and analyzed for genome wide copy number variation (CNV). The observed genomic variants correlated with CTC molecular and morphologic features previously associated with therapeutic resistance in subclonal populations.  

Within individual patients up to four distinct subclonal populations were detected harboring distinct sets of genomic alterations, many associated with therapeutic resistance. The presence of multiple distinct clonal populations was highly associated to patients with primary resistance to therapy and absent in patients responding to therapy. Further, CNV alterations associated with tumor suppressor loss or oncogene amplification were predominantly observed in resistant patients. 

"Successful treatment of cancer depends on understanding the heterogeneity of the patient's tumor burden and the driving genetic alterations behind their disease progression," said Murali Prahalad, Ph.D., president and CEO of Epic Sciences. "Our data show that the disease heterogeneity frequently present in late stage mCRPC patients may contain multiple CTC subtypes driven by multiple, and sometimes rare genetic alterations, which would likely be missed by analytical methods that only look at cell free DNA or other bulk measures of allelic frequency versus those examining single cells."

The study will be presented in Poster #247 (Abstract #11035), Tumor Biology Session on May 31, 8:00 a.m.

About Epic Sciences

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic's mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic's no cell left behind™ technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic's goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.
Further information is available on the Company's website, Stay in touch on Twitter @EpicSciences or on

Epic Sciences Investor Contact:
Michael Rodriguez, CFO, Epic Sciences,, +1.858.356.6610


SOURCE Epic Sciences, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference
2. Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico
3. NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting
4. NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting
5. A Finnish Company Enters International Markets With World Class Genetics Technology
6. Quest Diagnostics Introduces Comprehensive Opioid Therapy Genetic Test Based on CYP450 Biomarker License with Transgenomic
7. Gene By Gene Rejects BRCA1/2 Patent Infringement Claims by Myriad and Joins Ambry Genetics to Sue Myriad for Violating Federal Antitrust Laws
8. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
9. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
10. Investigación internacional: Compartir mejor la información genética en la salud humana
11. New Guidelines Released for Diagnosis, Surveillance and Management of Rare Genetic Disease Called Tuberous Sclerosis Complex
Post Your Comments:
(Date:8/27/2020)... Pa. (PRWEB) , ... August 27, 2020 , ... ... care coordination software, today announced the successful completion of their 2020 System and ... well as their HITRUST® interim assessment and MARS-E compliance assessment. These achievements reflect ...
(Date:8/27/2020)... ... ... Bleep LLC, maker of the DreamPort mask-less CPAP solution, announced today that ... , “In my line of work, a good night of sleep is critical to ... a Bleeping no brainer for me,” said Jensen. “From the moment I started using ...
(Date:8/27/2020)... ... ... The GHT Companies , a leading developer and distributor of nutraceutical products, ... with a press conference at its manufacturing facility in Vista. Here are the ... overall donation result exceeding $30,000 to Feeding San Diego, Who: Jim Rex, CEO, ...
Breaking Medicine Technology:
(Date:8/31/2020)... ... August 31, 2020 , ... Want to get moving, break ... Alliance Research Foundation (CPARF) is thrilled to launch its fourth annual STEPtember campaign in ... virtual challenge, STEPtember meets everyone wherever they are at this moment — encouraging people ...
(Date:8/31/2020)... ... ... economic outlook continues to put financial strain on many of us, so it just makes ... monthly expenses and put more into savings, if possible. , “That’s a great way to ... in place in case something were to happen to you,” says Lee Duncan, CMO & ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... outcomes for patients with advanced heart failure, today announced that the company has ... amount of $555,358 from the National Heart, Lung, and Blood Institute of the ...
(Date:8/28/2020)... ... August 28, 2020 , ... The 15 scholarships ... Lighthouse Health & Wellness mobile app and web-portal. NCPCV received a 2020 grant ... awards grants each year to organizations, such as Destination Imagination, which support and ...
(Date:8/28/2020)... ... August 28, 2020 , ... A July 27 article ... are at an increased risk of developing severe COVID-19 symptoms. The article does ... because the same organ systems that the coronavirus attacks are already suffering from ...
Breaking Medicine News(10 mins):